Expert Interview
Delving into the topline results from the phase 2b ODYSSEY clinical trial of suprachoroidal CLS-AX in wet AMD.
Ticker(s): CLSD, OCULInstitution: UCLA - Doheny Eye Institute
- Director, Artificial Intelligence & Imaging Research, Doheny Eye Institute and Professor of Ophthalmology at the University of California – Los Angeles (UCLA), David Geffen School of Medicine.
- Treats 1200 patients with wAMD.
- Principal Investigator for over 300 major clinical trials involving automated retinal image analysis, retinal substructure assessment, advanced retinal imaging technologies, and vision restoration approaches.
- Has authored over 550 peer-reviewed journal publications, over 300 abstracts and 20 book chapters and has given more than 450 presentations nationally and internationally.
1. What are the current unmet needs in treating wet AMD, particularly regarding treatment burden, disease progression, and response variability among patients?
Added By: catalin_admin2. How does the efficacy of second-generation treatments, like Vabysmo and Eylea HD, compare with emerging third-generation therapies such as TKIs, and what real-world durability expectations exist for these newer agents?
Added By: catalin_admin3. Given the Phase 2b ODYSSEY trial results for CLS-AX, how effective is suprachoroidal axitinib at reducing treatment frequency, and are there any concerns that combining TKIs with initial aflibercept loading might overestimate durability?
4. How do the clinical outcomes for CLS-AX, such as BCVA and CST maintenance, compare with existing anti-VEGF treatments, and are there concerns about potential long-term consequences of less stringent fluid management?
Added By: catalin_admin5. How might the suprachoroidal delivery route impact the adoption of CLS-AX, and are there specific considerations or advantages it may present over traditional injection methods?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
